Mylan NV
MYL
Delayed Nasdaq - 07/16 10:00:00 pm
36.4USD
-0.49%
Prev.36.5800
Open36.5400
High36.5400
Low36.2400
Volume1 749 413
Financials
Sales 2018 12 195 M
EBIT 2018 3 752 M
R. net 2018 1 295 M
Debt 2018 13 253 M
Rend. 2018 -
P/E ratio 2018 14,03
P/E ratio 2019 11,57
EV / Sales 2018 2,63x
EV / Sales 2019 2,30x
Capitalization 18 855 M
Company
Mylan NV is a pharmaceutical healthcare company.The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through the following geographical segments: North America, Europe, Rest of World, and...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-08-09 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival generic
RE
07/11Indivior warning on anti-opioid drug competition sends shares tumbling
RE
07/09MYLAN : Adds to Central Nervous System Portfolio With Launch of Generic ExelonŽ Patch
PR
07/02Novartis Injects Itself Into Planned Rollout of EpiPen Competitor -- Update
DJ
07/02Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks
AC
07/02ADAMIS PHARMA : Novartis Unit to Obtain U.S. Rights to Potential EpiPen Rival Symjepi
DJ
06/29Indivior gets breather after court extends order blocking generic rival
RE
06/28MYLAN STATEMENT : Morgantown Operations
PU
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralNeutral
Resistance38,547,646,9
Spread/Res.-5,4%-24%-22%
Spread/Supp.1,2%2,9%19%
Support36,035,430,5